Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers

被引:1
|
作者
Lin, Hui [1 ,2 ]
Tian, Yuan [1 ,2 ]
Tian, Ji-Xin [1 ,2 ]
Zhang, Zun-Jian [1 ,2 ]
Mao, Guo-Guang [3 ]
机构
[1] China Pharmaceut Univ, Ctr Instrumental Anal, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Minist Educ, Key Lab Drug Qual Control & Pharmacovigilance, Nanjing 210009, Peoples R China
[3] Wannan Med Coll, Dept Clin Pharmacol, Wuhu, Peoples R China
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2010年 / 60卷 / 03期
关键词
Acyclovir; Antiviral drugs; CAS; 59277-89-3; 124832-26-4; 214832-27-5; Valacyclovir; Valacyclovir hydrochloride; bioequivalence; pharmacokinetics; L-VALYL ESTER; ANTIVIRAL ACTIVITY; THERAPEUTIC-EFFICACY; ORAL VALACYCLOVIR; ACYCLOVIR; VALACICLOVIR; DISEASE; DRUG;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of the present study was to compare the bioavailability of valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule as test preparation and 150 mg/capsule commerciallty available original capsule of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 20 and 27. The study was conducted according to an open randomized, single blind, 2-way crossover study design with a wash-out phase of 7 days. Blood samples for pharmacokinetic profiling were taken up to 24 h post-dose. Valacyclovir hydrochloride is rapidly converted to acyclovir (CAS 59277-89-3) after oral administration, so the pharmacokinetcis and bioequivalence of valacyclovir hydrochloride can be studied by determining the plasma concnetratio of acyclovir. Plasma concentrations of acyclovir were determined witha validated liquid chromatography, tandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C-max) were 2.04 +/- 0.43 mu g mL and 2.01 +/- 0.50 mu g/mL; the median T-max were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t(1/2)) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h Values of AUC(0-t) demonstrate nearly identical bioavailability of valacyclovir hydrochloride from the examined formulations. AUC(0-15) were 6.70 +/- 1.26 mu g.h/mL and 6.96 +/- 1.25 g.h/mL. Areas under the plasma concentration-time curve (AUC(0-infinity)) were 6.90 +/- 1.36 mu g.h/ml and 7.15 +/- 1.31 mu g.h/mL. Both primary target parameters , AUC(0-infinity) and AUC(0-t) wre tested parametrically by analysis of variaance (ANOVA) and relative bioavailabilities were 96.69 7.89% for AUC(0-infinity) , 96.40 8.0% for AUC(0-15). Bioequivalence between test and reference preparation was demonstated fro both parameters AUC(0-infinity) and AUC(0-t). The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80-125%. It meant that the test formualtion was bioequivalnet to the reference formulation for valacyclovir hydrochloride.
引用
收藏
页码:162 / 167
页数:6
相关论文
共 50 条
  • [21] Bioequivalence of ticlopidine hydrochloride administered in single dose to healthy volunteers
    Marzo, A
    Dal Bo, L
    Rusca, A
    Zini, P
    PHARMACOLOGICAL RESEARCH, 2002, 46 (05) : 401 - 407
  • [22] Evaluation of Pharmacokinetics and Safety with Bioequivalence of Ibuprofen Sustained-Release Capsules of Two Formulations, in Chinese Healthy Volunteers: Bioequivalence Study
    Huang, Chunqi
    Yin, Zhou
    Yang, Yeqing
    Mo, Nan
    Yang, Hui
    Wang, Ying
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 1881 - 1888
  • [23] Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects
    Jiang, Xin
    Wang, Na
    Zhang, Zun-Jian
    Tian, Yuan
    Chen, Yun
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2008, 58 (07): : 363 - 366
  • [24] Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Domperidone After Single-Dose Administration in Healthy Chinese Subjects
    Ye, Libing
    Shen, Minmin
    Chen, Yingrong
    Li, Xiaofeng
    Xu, Min
    Yao, Chong
    Yang, Shuixin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1084 - 1091
  • [25] Pharmacokinetics and bioequivalence of two oral formulations of canagliflozin after single-dose administration in healthy Chinese subjects
    Hu, Wei
    Yang, Yaru
    Zhang, Qian
    Yang, Yang
    Zhou, Renpeng
    Lu, Chao
    Liu, Zeyuan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (01) : 57 - 66
  • [26] Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers
    Tangsucharit, P.
    Kampan, J.
    Kanjanawart, S.
    Gaysonsiri, D.
    Vannaprasaht, S.
    Tiamkao, S.
    Phunikhom, K.
    Simasathiansophon, S.
    Puapairoj, P.
    Tassaneeyakul, W.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (10) : 638 - 642
  • [27] Evaluation of the bioequivalence and pharmacokinetics of two formulations of rizatriptan after single oral administration in healthy volunteers
    Chen, J
    Jiang, WM
    Xie, YL
    Jin, L
    Mei, N
    Jiang, XG
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2005, 55 (07): : 355 - 358
  • [28] Pharmacokinetics and bioequivalence study of a generic desloratadine tablet formulation in healthy male volunteers
    Yeh, GC
    Deng, ST
    Lo, CY
    Chiang, PS
    Hsiong, CH
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2004, 54 (03): : 166 - 170
  • [29] Pharmacokinetic and Bioequivalence Studies of Trospium chloride after a Single-dose Administration in Healthy Chinese Volunteers
    Zhang, R.
    Yuan, G.
    Li, R.
    Liu, X.
    Wei, C.
    Wang, B.
    Gao, H.
    Guo, R.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (05): : 247 - 251
  • [30] Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers
    Sailer, Reinhard
    Arnold, Peter
    Erenmemisoglu, Aydin
    Martin, Wolfgang
    Tamur, Uygur
    Kanzik, Ilker
    Hincal, A. Atilla
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (07): : 462 - 466